{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:24:46Z","timestamp":1751531086710,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 65-year-old man with fluciclovine-avid metastatic prostate small cell carcinoma with prostate-specific antigen (PSA) 19.4 ng\/mL at diagnosis underwent system therapy and subsequent surgery and achieved hormonal response with PSA &lt;0.1 ng\/mL. An <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT scan 3 months after surgery was negative for disease. Although PSA remained &lt;0.1 ng\/mL, the rising carcinoembryonic antigen prompted an <jats:sup>18<\/jats:sup>F-FDG PET\/CT 6 weeks later. It showed multiple hypermetabolic lesions in the prostatectomy bed, liver, and right iliac bone, suggestive of malignant disease. The FDG-avid prostatectomy lesions were further confirmed on MRI. This case demonstrates that FDG PET\/CT has a role in suspected metastatic prostate small cell carcinoma with negative fluciclovine PET examination.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003864","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T22:03:25Z","timestamp":1629065005000},"page":"255-257","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma"],"prefix":"10.1097","volume":"47","author":[{"given":"Joshua","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, McGovern Medical School, The University of Texas Health Science Center at Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofan","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0b013e3181db4ce9","article-title":"F-18 FDG PET\/CT imaging in small cell prostate cancer","volume":"35","year":"2010","journal-title":"Clin Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/pros.22831","article-title":"Utility of FDG-PET in clinical neuroendocrine prostate cancer","volume":"74","year":"2014","journal-title":"Prostate"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/RLU.0b013e3181b06aed","article-title":"Widespread metastases in small cell carcinoma of the prostate on FDG PET\/CT","volume":"34","year":"2009","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1464-410X.2003.04297.x","article-title":"Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer","volume":"92","year":"2003","journal-title":"BJU Int"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1148\/rg.2019180139","article-title":"Review of 18F-fluciclovine PET for detection of recurrent prostate cancer","volume":"39","year":"2019","journal-title":"Radiographics"},{"key":"bib7-20250621","first-page":"1228","article-title":"Radiologist\u2019s take home pointers on F-18 fluciclovine (Axumin) PET\/CT imaging","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2020.38.6_suppl.24","article-title":"Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell\/neuroendocrine prostate cancer","volume":"38","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:46Z","timestamp":1750536406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003864","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}